Sonya Joshi, DO
Rheumatology · Dallas, TXNPI 1861955981
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 124 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Johnson & Johnson at 24.6% of the total. 2025 is the largest year on record at $1,686, 5.0 times the $338 reported in 2023. That places this record below the midpoint for rheumatology clinicians in TX, where the typical reported total is $3,779.
Across 124 payments — averaging $27.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$842
- Amgen$620
- AstraZeneca$586
- UCB, Inc.$261
- Daiichi Sankyo Inc.$224
- ANI Pharmaceuticals, Inc.$188
- plus $708 from 11 others
What the payments were for
- Food & beverage$3,35098%
- Education$802%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 26 | $842 |
| Amgen | 34 | $620 |
| AstraZeneca | 16 | $586 |
| UCB, Inc. | 4 | $261 |
| Daiichi Sankyo Inc. | 10 | $224 |
| ANI Pharmaceuticals, Inc. | 5 | $188 |
| Pfizer | 6 | $169 |
| Boehringer Ingelheim | 2 | $130 |
| AbbVie | 4 | $87 |
| GSK | 4 | $86 |
| E.r. Squibb & Sons, L.L.C. | 4 | $64 |
| Aurinia Pharma U.S., Inc. | 2 | $49 |
| Mallinckrodt Hospital Products Inc. | 2 | $39 |
| Lilly USA, LLC | 2 | $33 |
| Almatica Pharma LLC | 1 | $17 |
| Novartis | 1 | $17 |
| Sobi, Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tremfya$285
- SIMPONI ARIA$135
- FASENRA$124
- Cimzia$121
- PURIFIED CORTROPHIN GEL$120
- SAPHNELO$113
- OFEV$104
How this compares
$3,430 in reported general payments places this provider in the 45th percentile of 512 rheumatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MethotrexateMethotrexate Sodium | 83 | $3,186 |
| Mycophenolate Mofetil | 28 | $2,857 |
| Hydroxychloroquine Sulfate | 49 | $2,356 |
| Prednisone | 130 | $789 |
| Celecoxib | 27 | $449 |
| Meloxicam | 12 | $69 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Dallas
- John CushDallas$3.7M
- Zoran KurepaDallas$483K
- Giovanni GeslaniDallas$415K
- Dianne PetroneDallas$401K
- Stanley CohenDallas$318K
- Joanna GeslaniDallas$242K
- Sharad LakhanpalDallas$229K
- Iftikhar ChowdhryDallas$226K
- Srilatha KothandaramanDallas$140K
- Leyka BarbosaDallas$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.